CRP and asthenia: Non-severe COVID-19 (2), VZV (1), Worsening preexisting palmar warts (1), Mucosal candidiasis (1), Hepatic cytolysis (1), Blurred vision/diplopia (1), Asthenia (2), Isolated increased CRP levels (1)No patient discontinued anifrolumab because of an AE.